Patents by Inventor Robert Laprairie

Robert Laprairie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND USES OF PSILOCYBIN AND PSILOCIN
    Publication number: 20250375420
    Abstract: The present disclosure provides a method of treating or ameliorating a disease or disorder comprising administering to a subject a crystalline form of a composition comprising crystalline forms A, B, and C of psilocin and psilocybin. The disclosure further provides a method of stimulating neurogenesis or neurite growth resulting in an increase in neuronal length.
    Type: Application
    Filed: June 5, 2023
    Publication date: December 11, 2025
    Inventors: Peter Silverstone, Robert Laprairie, Deborah Kurrasch
  • USES OF A CO-CRYSTAL OF PSILOCYBIN AND PSILOCIN
    Publication number: 20250241935
    Abstract: The present disclosure provides a method of treating or ameliorating a disease or disorder in a subject in need thereof, comprising administering to the subject a composition comprising a crystalline form of psilocin and psilocybin, wherein the crystalline form is co-crystal form A of psilocin and psilocybin. The disclosure further provides methods of stimulating inducing neuroplasticity, increasing BDNF levels, and/or decreasing neuroinflammation.
    Type: Application
    Filed: April 18, 2025
    Publication date: July 31, 2025
    Inventors: Peter Silverstone, Robert Laprairie, Deborah Kurrasch
  • CO-ADMINISTRATION OF A CO-CRYSTAL OF PSILOCYBIN AND PSILOCIN WITH AN ATYPICAL ANTIPSYCHOTIC
    Publication number: 20250177422
    Abstract: The present disclosure provides a method of treating or ameliorating a mental health disorder or a central nervous system disorder in a subject in need thereof, comprising administering to the subject a composition comprising a crystalline form of psilocin and psilocybin, wherein the crystalline form is co-crystal form A of psilocin and psilocybin and an atypical antipsychotic.
    Type: Application
    Filed: November 8, 2024
    Publication date: June 5, 2025
    Inventors: Peter Silverstone, Robert Laprairie, Deborah Kurrasch
  • Uses of a co-crystal of psilocybin and psilocin
    Patent number: 12280068
    Abstract: The present disclosure provides a method of treating or ameliorating a disease or disorder in a subject in need thereof, comprising administering to the subject a composition comprising a crystalline form of psilocin and psilocybin, wherein the crystalline form is co-crystal form A of psilocin and psilocybin. The disclosure further provides methods of stimulating inducing neuroplasticity, increasing BDNF levels, and/or decreasing neuroinflammation.
    Type: Grant
    Filed: November 8, 2024
    Date of Patent: April 22, 2025
    Assignee: Zylorion Health Inc.
    Inventors: Peter Silverstone, Robert Laprairie, Deborah Kurrasch